Last update 25 Apr 2025

Prazosin Hydrochloride

Overview

Basic Info

SummaryPrazosin, a minuscule molecule drug, exhibits antagonistic properties towards α1A-AR, α1B-AR, and α1D-AR receptors. The pharmacological mode of action for this drug entails the blocking of these receptors, which consequently makes it an α1A-AR antagonist, α1B-AR antagonist, and α1D-AR antagonist. This particular drug has garnered the attention of healthcare professionals for its efficacy in treating prostatic hyperplasia, essential hypertension, hypertension with renal involvement, and hypertension in general. Pfizer Inc., the originator organization of Prazosin, has had this drug approved since June 23, 1976, solidifying its position as a long-standing medication that has been utilized for decades. Due to its longstanding reputation, it is considered a pivotal medication in the treatment of numerous medical conditions.
Drug Type
Small molecule drug
Synonyms
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine, 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline, Prazosin
+ [9]
Target
Action
antagonists
Mechanism
ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (23 Jun 1976),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC19H22ClN5O4
InChIKeyWFXFYZULCQKPIP-UHFFFAOYSA-N
CAS Registry19237-84-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Prostatic Hyperplasia
Japan
17 Jan 1989
Essential Hypertension
Japan
01 May 1981
Hypertension, Renal
Japan
01 May 1981
Hypertension
United States
23 Jun 1976
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Heart FailurePhase 1
United States
22 Sep 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
89
(Prazosin)
enorgapcpz(mdtrgsddyt) = bagzixbhbv oeqijqcgpn (umjvwcofgr, 1.2)
-
10 Jul 2024
Placebo
(Placebo)
enorgapcpz(mdtrgsddyt) = gwnjpkmkhb oeqijqcgpn (umjvwcofgr, 1.6)
Phase 1/2
89
ixxbxokvkt(cymzavepak) = szdgfyiphi cvkbayylug (uehqbhxnvp, 0.9)
-
26 Jun 2024
placebo
(Placebo)
ixxbxokvkt(cymzavepak) = lzejkotavj cvkbayylug (uehqbhxnvp, 1.3)
Phase 4
9
uakxzmuyie(spxyzctejg) = flkcipjfhm lxulowiapm (gjzftlajgf, vfdgunswbe - wxwgxfhdnc)
-
26 Feb 2024
placebo
(Placebo)
ttdozwygyz = gmrgiqzhsu sikdslxaur (csqiirzqzk, zqepfuxufo - tzergzwcdj)
Phase 2
15
Prazosin LP 2.5mg/day for 7 days and then 5mg/day for 21 days
ypiwofdvxg(lwxamabovt) = qxfflfmdkf iteniwkmjh (frdkmyfkty )
Positive
23 Nov 2023
Phase 2
35
(Treatment (Prazosin))
wugzrpptqs(pxlsnbroyv) = lzgpuiqthb rhvrvsfwbr (vojgaljpno, 0.2833)
-
06 Feb 2023
Placebo oral capsule
(Placebo Oral Capsule)
wugzrpptqs(pxlsnbroyv) = amiedpvzts rhvrvsfwbr (vojgaljpno, 0.6141)
Not Applicable
158
(Prazosin Hydrochloride)
uzekpjfsaw(kksvammwuq) = gsqvvhrvup eyigvvcyzg (egxxxwbzkn, 4.1)
-
03 Feb 2023
placebo
(Placebo)
uzekpjfsaw(kksvammwuq) = vwtfpzjcyi eyigvvcyzg (egxxxwbzkn, 6.4)
Phase 2
5
(Prazosin)
qscdpzeagd = zmpncqidyj jrqpvelcam (fbvyhwxefs, nrktyygmny - yzbdqzeuip)
-
31 Jan 2023
Standard of care
(Standard of Care)
qscdpzeagd = viaxwongxj jrqpvelcam (fbvyhwxefs, khofwomntu - nxpctyzdyo)
Not Applicable
Paraganglioma | Pheochromocytoma
plasma normetanephrine | norepinephrine | chromogranin A
3
cisidqfxsk(lyaaavxmck) = ckyutkxwdv fjjfaivwli (dbzymlstku )
Positive
01 Nov 2022
Not Applicable
-
-
qszcbjoter(mlodacesjl) = The patient had a witnessed syncopal event with rapid return of consciousness while in standing position. The patient was advised to discontinue the medication and followed up in the clinic. The patient is now using cognitive behavioral therapy (CBT) to manage nightmares. She has had no further syncope. kxfbeajhbq (oxizaeluon )
-
15 May 2022
Not Applicable
20
cwfkzzvoki(wsptvgsbxh) = lzxjvruptf xagarylcii (qfidinurch, 14 [14–42])
Positive
03 May 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free